Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Reports Increase in Q3 Revenue, R&D Spending, Net Income

NEW YORK, Oct. 28 - Qiagen today reported strong third-quarter revenue growth, an in increase in R&D spending, and a slight jump in net income.


For the period ended Sept. 30, Qiagen said net sales were $76.9 million compared with $63.3 million during the same quarter one year ago.


R&D spending in the third quarter increased to $7.3 million from $6.1 million year over year.


Net income for the quarter increased $7.3 million, or $.05 per share, from $6.2 million, or $.04 in the year-ago quarter, the company said.


Qiagen said it has roughly $51.8 million in cash and cash equivalents as of Sept. 30.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.